Anhui Fengyuan Pharmaceutical Co., Ltd. (SHE:000153)
China · Delayed Price · Currency is CNY 6.25
-0.16 (-2.50%)
Sep 10, 2026, 3:04 PM CST
SHE:000153 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,979 | 2,914 | 2,849 | 3,111 | 4,503 | 3,739 | |
Market Cap Growth | -6.71% | 2.28% | -8.42% | -30.92% | 20.43% | 36.14% |
Enterprise Value | 4,032 | 3,649 | 3,512 | 3,661 | 4,669 | 4,077 |
Last Close Price | 6.41 | 6.15 | 5.92 | 6.34 | 9.08 | 7.92 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 31.55 | 29.31 | 17.71 | 19.53 | 29.16 | 30.41 |
Forward PE | - | 30.50 | 30.50 | 30.50 | 30.50 | 30.50 |
PS Ratio | 0.85 | 0.76 | 0.67 | 0.73 | 1.13 | 1.02 |
PB Ratio | 1.36 | 1.37 | 1.39 | 1.62 | 2.57 | 2.11 |
P/TBV Ratio | 1.56 | 1.58 | 1.61 | 1.85 | 2.91 | 2.38 |
P/FCF Ratio | 61.39 | - | - | 30.31 | 12.57 | 35.69 |
P/OCF Ratio | 17.04 | 24.43 | 22.57 | 12.21 | 10.24 | 14.13 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 1.15 | 0.95 | 0.82 | 0.86 | 1.17 | 1.12 |
EV/EBITDA Ratio | 15.04 | 14.50 | 12.88 | 12.43 | 17.73 | 16.87 |
EV/EBIT Ratio | 31.09 | 27.94 | 20.43 | 18.91 | 27.49 | 26.13 |
EV/FCF Ratio | 83.10 | - | - | 35.67 | 13.03 | 38.91 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.69 | 0.51 | 0.48 | 0.36 | 0.42 | 0.35 |
Debt / EBITDA Ratio | 5.64 | 3.90 | 3.28 | 2.15 | 2.53 | 2.31 |
Debt / FCF Ratio | 31.17 | - | - | 6.70 | 2.06 | 5.97 |
Net Debt / Equity Ratio | 0.47 | 0.33 | 0.36 | 0.19 | 0.17 | 0.19 |
Net Debt / EBITDA Ratio | 4.12 | 2.79 | 2.69 | 1.25 | 1.15 | 1.42 |
Net Debt / FCF Ratio | 21.27 | -6.91 | -41.27 | 3.58 | 0.85 | 3.27 |
Asset Turnover | 0.70 | 0.79 | 0.94 | 0.97 | 0.94 | 0.95 |
Inventory Turnover | 5.26 | 5.56 | 5.76 | 5.00 | 4.26 | 4.35 |
Quick Ratio | 0.60 | 0.62 | 0.59 | 0.60 | 0.53 | 0.57 |
Current Ratio | 0.85 | 0.88 | 0.90 | 0.95 | 0.89 | 0.96 |
Return on Equity (ROE) | 4.19% | 4.54% | 7.95% | 8.56% | 8.56% | 7.32% |
Return on Assets (ROA) | 1.63% | 1.67% | 2.36% | 2.73% | 2.49% | 2.54% |
Return on Invested Capital (ROIC) | 3.43% | 3.53% | 5.13% | 6.52% | 6.07% | 5.92% |
Return on Capital Employed (ROCE) | 4.90% | 4.90% | 6.80% | 8.10% | 8.00% | 7.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.17% | 3.41% | 5.64% | 5.12% | 3.43% | 3.29% |
FCF Yield | 1.63% | -3.48% | -0.62% | 3.30% | 7.95% | 2.80% |
Dividend Yield | 1.58% | 1.63% | 1.69% | 1.69% | 0.79% | 0.90% |
Payout Ratio | 85.78% | 81.64% | 44.87% | 40.29% | 37.22% | 21.37% |
Buyback Yield / Dilution | - | -0.01% | 0.05% | -4.71% | -1.59% | -0.03% |
Total Shareholder Return | 1.58% | 1.61% | 1.74% | -3.02% | -0.81% | 0.87% |